Boston Scientific launches Captivator EMR Device

Boston Scientific has announced the launch of its new Captivator EMR (endoscopic mucosal resection) Device for treating diseases of the upper gastrointestinal tract.

Providing a minimally invasive alternative to an oesophagectomy, EMR allows for the staging and removal of precancerous tissue and early oesophageal cancer in the upper gastrointestinal tract during an endoscopic outpatient procedure.

This would avoid the need to remove part of the oesophagus, with the Captivator EMR Device offering benefits such as enhanced visualisation, control and easy passage of devices.

The new system is being made available initially in the US, Europe, Singapore, Australia and Puerto Rico.

David Pierce, senior vice-president and president for endoscopy at Boston Scientific, said: "The Captivator EMR Device provides physicians and patients with an important new option for staging and treating early oesophageal neoplasia and cancer."

The firm is also launching a registry to study the performance of the Captivator EMR Device for endoscopic resection of early neoplasia, with approximately 300 patients to be enrolled across 16 clinical centers in eight countries. It is expected to be completed in 2016.